neurostimulation
(5)
The Battery That Left the Body
Neuspera Medical moved the battery from inside the body to a wearable disc. Its bet: people with urinary urge incontinence may welcome a daily ritual if it spares them a second implanted device.
Otolith Labs
Otolith Labs is a Washington, D.C. medical device company building the first wearable to treat vertigo, motion sickness and virtual-reality sickness. Its patented non-invasive Vestibular Resonance Therapy (nVRT) uses precisely tuned bone-conduction vibrations to interact with the motion sensors of the inner ear, quieting the faulty balance signals that cause dizziness. The head-worn OtoBand has been tested on hundreds of subjects, carries an FDA Breakthrough Device Designation, and is pursuing FDA clearance through the De Novo pathway.
XII Medical
XII Medical is a Union City, California medical device company building a minimally invasive neuromodulation therapy for obstructive sleep apnea (OSA). Founded in 2017 and led by CEO Garrett Schwab, the company is developing an implantable platform designed to be smaller, more flexible and easier to implant than existing nerve-stimulation systems - an alternative for the estimated 425 million people worldwide with moderate-to-severe OSA who struggle with CPAP masks. Backed by Cleveland Clinic, Ajax Health, Omega Funds and Intuitive Ventures, XII Medical closed a $45M Series B in August 2024 to fund product and clinical development.
NeuroBionics
NeuroBionics is a Boston-area neurotechnology company spun out of more than a decade of MIT research. It builds hair-thin, flexible bioelectronic fibers that reach neural targets through the body's blood vessels instead of open surgery. Its lead device, evStim, aims to deliver deep brain and peripheral nerve stimulation endovascularly, potentially widening access to neuromodulation therapy for conditions like Parkinson's disease, epilepsy, chronic pain, and depression.
Samphire Neuroscience
Samphire Neuroscience is a London-based neurotechnology company building drug-free, hormone-free wearables for women's health. Its flagship product, Nettle, is a headband that uses transcranial direct current stimulation (tDCS) to gently modulate the brain regions tied to mood and pain, worn 20 minutes a day in the run-up to menstruation. Marketed as the first EU-cleared (CE-certified) neuromodulation device for women's health, Nettle targets PMS, PMDD, menstrual pain and related hormonal conditions. Founded in 2021 by neuroscientist Emilė Radytė and IP lawyer Alex Cook, the company has raised roughly $7.77M across pre-seed, seed and Series A rounds.